NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) announced that NEREUS™ (tradipitant), described as the first new U.S. prescription treatment in 47 years for prevention of vomiting induced by motion, will sponsor the No. 47 Rahal Letterman Lanigan Racing entry in the NTT IndyCar Series. The 2026 partnership highlights NEREUS™ as a selective NK-1 receptor antagonist and will feature prominent NEREUS™ branding on the No. 47 IndyCar at select series events.
Details
News Market Reaction – VNDA
On Jul 16, the first trading day after this news, VNDA closed 6.84% below the previous close. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner recorded 12 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 16 session.
Key Figures
- Gap since last treatment
- 47 years
- Time since last new U.S. motion sickness treatment
- Sponsored car number
- No. 47
- NTT IndyCar Series entry sponsored by NEREUS
Historical Context
-
FDA Rare Pediatric Disease Designation for CMT2S therapy VCA-894A.
-
Japan orphan drug designation for imsidolimab in generalized pustular psoriasis.
-
Planned participation in three May 2026 health care investor conferences.
-
Q1 2026 results with NEREUS launch and raised full-year revenue guidance.
-
U.S. commercial availability of NEREUS for motion-induced vomiting prevention.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nk-1 receptor antagonist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The partnership aligns NEREUS'™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.
This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in
"Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda.
The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.
About NEREUS™ (tradipitant)
NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
About Rahal Letterman Lanigan Racing
Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
Follow us on X @vandapharma
View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html
SOURCE Vanda Pharmaceuticals Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.